{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:45:09Z","timestamp":1787168709370,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["DJCLS 04 R\/2017"],"award-info":[{"award-number":["DJCLS 04 R\/2017"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["DJCLS 04 R\/2017"],"award-info":[{"award-number":["DJCLS 04 R\/2017"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112282"],"award-info":[{"award-number":["70112282"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112282"],"award-info":[{"award-number":["70112282"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovative Medical Research of the University of M\u00fcnster Medical School, Germany","award":["121314"],"award-info":[{"award-number":["121314"]}]},{"name":"Innovative Medical Research of the University of M\u00fcnster Medical School, Germany","award":["111501"],"award-info":[{"award-number":["111501"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG CRC1009B03"],"award-info":[{"award-number":["DFG CRC1009B03"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG EXC1003"],"award-info":[{"award-number":["DFG EXC1003"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG EXC1003"],"award-info":[{"award-number":["DFG EXC1003"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["6103\/3-1"],"award-info":[{"award-number":["6103\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2021_EKTP13"],"award-info":[{"award-number":["2021_EKTP13"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2021_EKTP13"],"award-info":[{"award-number":["2021_EKTP13"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2021_EKTP13"],"award-info":[{"award-number":["2021_EKTP13"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2014.054.1"],"award-info":[{"award-number":["2014.054.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2014.054.1"],"award-info":[{"award-number":["2014.054.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Interdisciplinary Centre for Clinical Research Muenster, Germany","award":["B\u00e4u2\/009\/19"],"award-info":[{"award-number":["B\u00e4u2\/009\/19"]}]},{"DOI":"10.13039\/501100004869","name":"Westf\u00e4lische Wilhelms-Universit\u00e4t M\u00fcnster","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) is a fatal clonal hematopoietic malignancy, which results from the accumulation of several genetic aberrations in myeloid progenitor cells, with a worldwide 5-year survival prognosis of about 30%. Therefore, the development of more effective therapeutics with novel mode of action is urgently demanded. One common mutated gene in the AML is the DNA-methyltransferase DNMT3A whose function in the development and maintenance of AML is still unclear. To specifically target \u201cundruggable\u201d oncogenes, we initially invented an RNAi-based targeted therapy option that uses the internalization capacity of a colorectal cancer specific anti-EGFR-antibody bound to cationic protamine and the anionic siRNA. Here, we present a new experimental platform technology of molecular oncogene targeting in AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our AML-targeting system consists of an internalizing anti-CD33-antibody\u2013protamine conjugate, which together with anionic molecules such as siRNA or ibrutinib-Cy3.5 and cationic free protamine spontaneously assembles into vesicular nanocarriers in aqueous solution. These nanocarriers were analyzed concerning their physical properties and relevant characteristics in vitro in cell lines and in vivo in xenograft tumor models and patient-derived xenograft leukemia models with the aim to prepare them for translation into clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The nanocarriers formed depend on a balanced electrostatic combination of the positively charged cationic protamine-conjugated anti-CD33 antibody, unbound cationic protamine and the anionic cargo. This nanocarrier transports its cargo safely into the AML target cells and has therapeutic activity against AML in vitro and in vivo. siRNAs directed specifically against two common mutated genes in the AML, the DNA-methyltransferase DNMT3A and FLT3-ITD lead to a reduction of clonal growth in vitro in AML cell lines and inhibit tumor growth in vivo in xenotransplanted cell lines. Moreover, oncogene knockdown of DNMT3A leads to increased survival of mice carrying leukemia patient-derived xenografts. Furthermore, an anionic derivative of the approved Bruton\u2019s kinase (BTK) inhibitor ibrutinib, ibrutinib-Cy3.5, is also transported by this nanocarrier into AML cells and decreases colony formation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We report important results toward innovative personalized, targeted treatment options via electrostatic nanocarrier therapy in AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-022-01390-5","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:41:05Z","timestamp":1669902065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Electrostatic anti-CD33-antibody\u2013protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia"],"prefix":"10.1186","volume":"15","author":[{"given":"Nicole","family":"B\u00e4umer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Scheller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Apel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbaiah Chary","family":"Nimmagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Grunert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neele","family":"Kellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Peipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareetha","family":"Kailayangiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias Ezequiel","family":"Gutierrez Suburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian A.","family":"Strassert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilo","family":"Greune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"R\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Dersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rossig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schw\u00f6ppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Khandanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"B\u00e4umer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"1390_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"1390_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I de Kouchkovsky","year":"2016","unstructured":"de Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6: e441. https:\/\/doi.org\/10.1038\/bcj.2016.50.","journal-title":"Blood Cancer J"},{"key":"1390_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nprot.2015.137","volume":"11","author":"N B\u00e4umer","year":"2016","unstructured":"B\u00e4umer N, Appel N, Terheyden L, Buchholz F, Rossig C, M\u00fcller-Tidow C, et al. Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown. Nat Protoc. 2016;11:22\u201336. https:\/\/doi.org\/10.1038\/nprot.2015.137.","journal-title":"Nat Protoc"},{"key":"1390_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200163","volume":"13","author":"N B\u00e4umer","year":"2018","unstructured":"B\u00e4umer N, Rehk\u00e4mper J, Appel N, Terheyden L, Hartmann W, Wardelmann E, et al. Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. PLoS ONE. 2018;13: e0200163. https:\/\/doi.org\/10.1371\/journal.pone.0200163.","journal-title":"PLoS ONE"},{"key":"1390_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-13-2017","volume":"21","author":"S B\u00e4umer","year":"2015","unstructured":"B\u00e4umer S, B\u00e4umer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, et al. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. Clin Cancer Res. 2015;21:1383\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2017.","journal-title":"Clin Cancer Res"},{"key":"1390_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202109769","volume":"61","author":"A Faust","year":"2022","unstructured":"Faust A, B\u00e4umer N, Schl\u00fctermann A, Becht M, Greune L, Geyer C, et al. Tumor-cell-specific targeting of ibrutinib: introducing electrostatic antibody-inhibitor conjugates (AiCs). Angew Chem Int Ed Engl. 2022;61: e202109769. https:\/\/doi.org\/10.1002\/anie.202109769.","journal-title":"Angew Chem Int Ed Engl"},{"key":"1390_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-pharmtox-010715-103633","volume":"56","author":"ML Bobbin","year":"2016","unstructured":"Bobbin ML, Rossi JJ. RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol. 2016;56:103\u201322. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010715-103633.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1390_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han S-P. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18:421\u201346. https:\/\/doi.org\/10.1038\/s41573-019-0017-4.","journal-title":"Nat Rev Drug Discov"},{"key":"1390_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1208760.","journal-title":"N Engl J Med"},{"key":"1390_CR10","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/s41388-022-02241-w","volume":"41","author":"N B\u00e4umer","year":"2022","unstructured":"B\u00e4umer N, Tiemann J, Scheller A, Meyer T, Wittmann L, Suburu MEG, et al. Targeted siRNA nanocarrier: a platform technology for cancer treatment. Oncogene. 2022;41:2210\u201324. https:\/\/doi.org\/10.1038\/s41388-022-02241-w.","journal-title":"Oncogene"},{"key":"1390_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.cell.2017.01.021","volume":"168","author":"DH Spencer","year":"2017","unstructured":"Spencer DH, Russler-Germain DA, Ketkar S, Helton NM, Lamprecht TL, Fulton RS, et al. CpG Island hypermethylation mediated by DNMT3A Is a consequence of AML progression. Cell. 2017;168:801-816.e13. https:\/\/doi.org\/10.1016\/j.cell.2017.01.021.","journal-title":"Cell"},{"key":"1390_CR12","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424\u201333.","journal-title":"N Engl J Med"},{"key":"1390_CR13","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.2011.35.4894","volume":"29","author":"F Thol","year":"2011","unstructured":"Thol F, Damm F, L\u00fcdeking A, Winschel C, Wagner K, Morgan M, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29:2889\u201396.","journal-title":"J Clin Oncol"},{"key":"1390_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ccr.2014.02.010","volume":"25","author":"DA Russler-Germain","year":"2014","unstructured":"Russler-Germain DA, Spencer DH, Young MA, Lamprecht TL, Miller CA, Fulton R, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014;25:442\u201354. https:\/\/doi.org\/10.1016\/j.ccr.2014.02.010.","journal-title":"Cancer Cell"},{"key":"1390_CR15","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1200\/JCO.2014.59.2022","volume":"33","author":"RE Gale","year":"2015","unstructured":"Gale RE, Lamb K, Allen C, El-Sharkawi D, Stowe C, Jenkinson S, et al. Simpson\u2019s paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015;33:2072\u201383. https:\/\/doi.org\/10.1200\/JCO.2014.59.2022.","journal-title":"J Clin Oncol"},{"key":"1390_CR16","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1182\/blood-2012-10-461624","volume":"121","author":"VI Gaidzik","year":"2013","unstructured":"Gaidzik VI, Schlenk RF, Paschka P, St\u00f6lzle A, Sp\u00e4th D, Kuendgen A, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood. 2013;121:4769\u201377. https:\/\/doi.org\/10.1182\/blood-2012-10-461624.","journal-title":"Blood"},{"key":"1390_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030320","author":"L Brunetti","year":"2017","unstructured":"Brunetti L, Gundry MC, Goodell MA. DNMT3A in Leukemia. Cold Spring Harb Perspect Med. 2017. https:\/\/doi.org\/10.1101\/cshperspect.a030320.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"12\/04","key":"1390_CR18","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.biomaterials.2009.11.001","volume":"2009","author":"YS Choi","year":"2009","unstructured":"Choi YS, Lee JY, Suh JS, Kwon YM, Lee SJ, Chung JK, et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials. 2009;2009(12\/04):1429\u201343. https:\/\/doi.org\/10.1016\/j.biomaterials.2009.11.001.","journal-title":"Biomaterials"},{"key":"1390_CR19","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/leu.2017.187","volume":"31","author":"CD Godwin","year":"2017","unstructured":"Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31:1855\u201368.","journal-title":"Leukemia"},{"key":"1390_CR20","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1038\/sj.onc.1210364","volume":"26","author":"L Pagano","year":"2007","unstructured":"Pagano L, Fianchi L, Caira M, Rutella S, Leone G. The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007;26:3679\u201390.","journal-title":"Oncogene"},{"key":"1390_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ph13090245","author":"N Joubert","year":"2020","unstructured":"Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-drug conjugates: the last decade. Pharmaceuticals (Basel). 2020. https:\/\/doi.org\/10.3390\/ph13090245.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1390_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/sj.leu.2403205","volume":"18","author":"I Jedema","year":"2004","unstructured":"Jedema I, Barge RMY, van der Velden VHJ, Nijmeijer BA, van Dongen JJM, Willemze R, Falkenburg JHF. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia. 2004;18:316\u201325. https:\/\/doi.org\/10.1038\/sj.leu.2403205.","journal-title":"Leukemia"},{"key":"1390_CR23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331. https:\/\/doi.org\/10.1038\/s41586-018-0623-z.","journal-title":"Nature"},{"key":"1390_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clml.2019.05.008","volume":"19","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS. Clinical experience with Ibrutinib alone or in combination with either cytarabine or Azacitidine in patients with acute myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019;19:509-515.e1. https:\/\/doi.org\/10.1016\/j.clml.2019.05.008.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1390_CR25","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/s41375-020-0764-6","volume":"34","author":"CA Eide","year":"2020","unstructured":"Eide CA, Kurtz SE, Kaempf A, Long N, Agarwal A, Tognon CE, et al. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Leukemia. 2020;34:2342\u201353. https:\/\/doi.org\/10.1038\/s41375-020-0764-6.","journal-title":"Leukemia"},{"key":"1390_CR26","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/10428194.2017.1349899","volume":"59","author":"M Schaffer","year":"2018","unstructured":"Schaffer M, Chaturvedi S, Davis C, Aquino R, Stepanchick E, Versele M, et al. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. Leuk Lymphoma. 2018;59:931\u201340. https:\/\/doi.org\/10.1080\/10428194.2017.1349899.","journal-title":"Leuk Lymphoma"},{"key":"1390_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W. HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btu638.","journal-title":"Bioinformatics"},{"key":"1390_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"key":"1390_CR29","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1390_CR30","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","volume":"49","author":"D Szklarczyk","year":"2021","unstructured":"Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res. 2021;49:D605\u201312. https:\/\/doi.org\/10.1093\/nar\/gkaa1074.","journal-title":"Nucleic Acids Res"},{"key":"1390_CR31","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gku1003","volume":"43","author":"D Szklarczyk","year":"2015","unstructured":"Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447\u201352. https:\/\/doi.org\/10.1093\/nar\/gku1003.","journal-title":"Nucleic Acids Res"},{"issue":"Suppl 4","key":"1390_CR32","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8","author":"C-H Chin","year":"2014","unstructured":"Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11. https:\/\/doi.org\/10.1186\/1752-0509-8-S4-S11.","journal-title":"BMC Syst Biol"},{"key":"1390_CR33","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/s41598-020-79235-9","volume":"11","author":"H Ma","year":"2021","unstructured":"Ma H, He Z, Chen J, Zhang X, Song P. Identifying of biomarkers associated with gastric cancer based on 11 topological analysis methods of CytoHubba. Sci Rep. 2021;11:1331. https:\/\/doi.org\/10.1038\/s41598-020-79235-9.","journal-title":"Sci Rep"},{"key":"1390_CR34","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504. https:\/\/doi.org\/10.1101\/gr.1239303.","journal-title":"Genome Res"},{"key":"1390_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.647353","volume":"12","author":"R Huang","year":"2021","unstructured":"Huang R, Liu J, Li H, Zheng L, Jin H, Zhang Y, et al. Identification of hub genes and their correlation with immune infiltration cells in hepatocellular carcinoma based on GEO and TCGA databases. Front Genet. 2021;12: 647353. https:\/\/doi.org\/10.3389\/fgene.2021.647353.","journal-title":"Front Genet"},{"key":"1390_CR36","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/1535-7163.MCT-13-0858","volume":"13","author":"K Keegan","year":"2014","unstructured":"Keegan K, Li C, Li Z, Ma J, Ragains M, Coberly S, et al. Preclinical evaluation of AMG 925, a FLT3\/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. Mol Cancer Ther. 2014;13:880\u20139. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0858.","journal-title":"Mol Cancer Ther"},{"key":"1390_CR37","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","volume":"26","author":"S Jin","year":"2020","unstructured":"Jin S, Cojocari D, Purkal JJ, Popovic R, Talaty NN, Xiao Y, et al. 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin Cancer Res. 2020;26:3371\u201383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1900.","journal-title":"Clin Cancer Res"},{"key":"1390_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41420-021-00465-5","volume":"7","author":"DD Fang","year":"2021","unstructured":"Fang DD, Tang Q, Kong Y, Rong T, Wang Q, Li N, et al. MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discov. 2021;7:90. https:\/\/doi.org\/10.1038\/s41420-021-00465-5.","journal-title":"Cell Death Discov"},{"key":"1390_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1158\/2159-8290.CD-16-0008","volume":"6","author":"SE Meyer","year":"2016","unstructured":"Meyer SE, Qin T, Muench DE, Masuda K, Venkatasubramanian M, Orr E, et al. DNMT3A haploinsufficiency transforms FLT3ITD myeloproliferative disease into a rapid, spontaneous, and fully penetrant acute myeloid leukemia. Cancer Discov. 2016;6:501\u201315. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0008.","journal-title":"Cancer Discov"},{"key":"1390_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, Crommelin DJA. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021;601: 120586. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120586.","journal-title":"Int J Pharm"},{"key":"1390_CR41","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"1390_CR42","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","volume":"168","author":"DM Hyman","year":"2017","unstructured":"Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell. 2017;168:584\u201399. https:\/\/doi.org\/10.1016\/j.cell.2016.12.015.","journal-title":"Cell"},{"key":"1390_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/17460441.2021.1969359","volume":"17","author":"G Zhang","year":"2022","unstructured":"Zhang G, Zhang J, Gao Y, Li Y, Li Y. Strategies for targeting undruggable targets. Expert Opin Drug Discov. 2022;17:55\u201369. https:\/\/doi.org\/10.1080\/17460441.2021.1969359.","journal-title":"Expert Opin Drug Discov"},{"key":"1390_CR44","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2009.05.006","volume":"137","author":"J Luo","year":"2009","unstructured":"Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009;137:835\u201348. https:\/\/doi.org\/10.1016\/j.cell.2009.05.006.","journal-title":"Cell"},{"key":"1390_CR45","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cell.2008.09.061","volume":"135","author":"L Zender","year":"2008","unstructured":"Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 2008;135:852\u201364. https:\/\/doi.org\/10.1016\/j.cell.2008.09.061.","journal-title":"Cell"},{"key":"1390_CR46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.5681\/apb.2014.046","volume":"4","author":"B Mansoori","year":"2014","unstructured":"Mansoori B, Sandoghchian Shotorbani S, Baradaran B. RNA interference and its role in cancer therapy. Adv Pharm Bull. 2014;4:313\u201321. https:\/\/doi.org\/10.5681\/apb.2014.046.","journal-title":"Adv Pharm Bull"},{"key":"1390_CR47","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651\u201368. https:\/\/doi.org\/10.1038\/s41577-020-0306-5.","journal-title":"Nat Rev Immunol"},{"key":"1390_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.868695","volume":"13","author":"SK Kim","year":"2022","unstructured":"Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol. 2022;13: 868695. https:\/\/doi.org\/10.3389\/fphar.2022.868695.","journal-title":"Front Pharmacol"},{"key":"1390_CR49","first-page":"514","volume":"42","author":"CL Ventola","year":"2017","unstructured":"Ventola CL. Cancer immunotherapy, Part 3: challenges and future trends. P T. 2017;42:514\u201321.","journal-title":"P T"},{"key":"1390_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/cdd.2017.188","volume":"25","author":"JC Reed","year":"2018","unstructured":"Reed JC. Bcl-2 on the brink of breakthroughs in cancer treatment. Cell Death Differ. 2018;25:3\u20136. https:\/\/doi.org\/10.1038\/cdd.2017.188.","journal-title":"Cell Death Differ"},{"key":"1390_CR51","doi-asserted-by":"publisher","unstructured":"Varghese AM, Ang C, Dimaio CJ, Javle MM, Gutierrez M, Yarom N, et al. A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT). J. Clin. Oncol. 2020;38:TPS4672-TPS4672. doi:https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS4672.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4672"},{"key":"1390_CR52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang X-J. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5:101. https:\/\/doi.org\/10.1038\/s41392-020-0207-x.","journal-title":"Signal Transduct Target Ther"},{"key":"1390_CR53","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28:109\u201318. https:\/\/doi.org\/10.1089\/nat.2018.0736.","journal-title":"Nucleic Acid Ther"},{"key":"1390_CR54","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/febs.12721","volume":"281","author":"J Mart\u00ednez-Oliv\u00e1n","year":"2014","unstructured":"Mart\u00ednez-Oliv\u00e1n J, Arias-Moreno X, Velazquez-Campoy A, Millet O, Sancho J. LDL receptor\/lipoprotein recognition: endosomal weakening of ApoB and ApoE binding to the convex face of the LR5 repeat. FEBS J. 2014;281:1534\u201346. https:\/\/doi.org\/10.1111\/febs.12721.","journal-title":"FEBS J"},{"key":"1390_CR55","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673\u201394. https:\/\/doi.org\/10.1038\/s41573-020-0075-7.","journal-title":"Nat Rev Drug Discov"},{"key":"1390_CR56","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1093\/nar\/gkaa365","volume":"48","author":"OA Ukogu","year":"2020","unstructured":"Ukogu OA, Smith AD, Devenica LM, Bediako H, McMillan RB, Ma Y, et al. Protamine loops DNA in multiple steps. Nucleic Acids Res. 2020;48:6108\u201319. https:\/\/doi.org\/10.1093\/nar\/gkaa365.","journal-title":"Nucleic Acids Res"},{"key":"1390_CR57","doi-asserted-by":"publisher","first-page":"20088","DOI":"10.1074\/jbc.M312777200","volume":"279","author":"ID Vilfan","year":"2004","unstructured":"Vilfan ID, Conwell CC, Hud NV. Formation of native-like mammalian sperm cell chromatin with folded bull protamine. J Biol Chem. 2004;279:20088\u201395. https:\/\/doi.org\/10.1074\/jbc.M312777200.","journal-title":"J Biol Chem"},{"key":"1390_CR58","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/molbev\/msk021","volume":"23","author":"JM Eir\u00edn-L\u00f3pez","year":"2006","unstructured":"Eir\u00edn-L\u00f3pez JM, Lewis JD, Le Howe A, Ausi\u00f3 J. Common phylogenetic origin of protamine-like (PL) proteins and histone H1: Evidence from bivalve PL genes. Mol Biol Evol. 2006;23:1304\u201317. https:\/\/doi.org\/10.1093\/molbev\/msk021.","journal-title":"Mol Biol Evol"},{"key":"1390_CR59","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nbt1101","volume":"23","author":"E Song","year":"2005","unstructured":"Song E, Zhu P, Lee S-K, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709\u201317. https:\/\/doi.org\/10.1038\/nbt1101.","journal-title":"Nat Biotechnol"},{"key":"1390_CR60","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217\u201323. https:\/\/doi.org\/10.1038\/s41586-019-1694-1.","journal-title":"Nature"},{"key":"1390_CR61","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","volume":"128","author":"KH Metzeler","year":"2016","unstructured":"Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, G\u00f6rlich D, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128:686\u201398. https:\/\/doi.org\/10.1182\/blood-2016-01-693879.","journal-title":"Blood"},{"key":"1390_CR62","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","volume":"560","author":"JD Phelan","year":"2018","unstructured":"Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560:387\u201391. https:\/\/doi.org\/10.1038\/s41586-018-0290-0.","journal-title":"Nature"},{"key":"1390_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082123","author":"J Zhang","year":"2020","unstructured":"Zhang J, Yang C, Wu C, Cui W, Wang L. DNA methyltransferases in cancer: biology, paradox, aberrations, and targeted therapy. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12082123.","journal-title":"Cancers (Basel)"},{"key":"1390_CR64","doi-asserted-by":"publisher","first-page":"18061","DOI":"10.1073\/pnas.1114946108","volume":"108","author":"Q Gao","year":"2011","unstructured":"Gao Q, Steine EJ, Barrasa MI, Hockemeyer D, Pawlak M, Fu D, et al. Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl Acad Sci U S A. 2011;108:18061\u20136. https:\/\/doi.org\/10.1073\/pnas.1114946108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1390_CR65","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1158\/0008-5472.CAN-18-3275","volume":"79","author":"R Lu","year":"2019","unstructured":"Lu R, Wang J, Ren Z, Yin J, Wang Y, Cai L, Wang GG. A Model system for studying the DNMT3A hotspot mutation (DNMT3AR882) demonstrates a causal relationship between its dominant-negative effect and leukemogenesis. Cancer Res. 2019;79:3583\u201394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3275.","journal-title":"Cancer Res"},{"key":"1390_CR66","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s43018-021-00213-9","volume":"2","author":"M Scheller","year":"2021","unstructured":"Scheller M, Ludwig AK, G\u00f6llner S, Rohde C, Kr\u00e4mer S, St\u00e4ble S, et al. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. Nat Cancer. 2021;2:527\u201344. https:\/\/doi.org\/10.1038\/s43018-021-00213-9.","journal-title":"Nat Cancer"},{"key":"1390_CR67","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood.2021011320","volume":"138","author":"M Rossi","year":"2021","unstructured":"Rossi M, Meggendorfer M, Zampini M, Tettamanti M, Riva E, Travaglino E, et al. Clinical relevance of clonal hematopoiesis in persons aged \u226580 years. Blood. 2021;138:2093\u2013105. https:\/\/doi.org\/10.1182\/blood.2021011320.","journal-title":"Blood"},{"key":"1390_CR68","doi-asserted-by":"publisher","first-page":"5473197","DOI":"10.1155\/2017\/5473197","volume":"2017","author":"SF Chaudry","year":"2017","unstructured":"Chaudry SF, Chevassut TJT. Epigenetic guardian: a review of the DNA methyltransferase DNMT3A in acute myeloid leukaemia and clonal haematopoiesis. Biomed Res Int. 2017;2017:5473197. https:\/\/doi.org\/10.1155\/2017\/5473197.","journal-title":"Biomed Res Int"},{"key":"1390_CR69","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-018-0675-4","volume":"11","author":"M Wu","year":"2018","unstructured":"Wu M, Li C, Zhu X. FLT3 inhibitors in acute myeloid leukemia. J Hematol Oncol. 2018;11:133. https:\/\/doi.org\/10.1186\/s13045-018-0675-4.","journal-title":"J Hematol Oncol"},{"key":"1390_CR70","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.2217\/fon-2017-0160","volume":"13","author":"MM Patnaik","year":"2017","unstructured":"Patnaik MM. Midostaurin for the treatment of acute myeloid leukemia. Future Oncol. 2017;13:1853\u201371. https:\/\/doi.org\/10.2217\/fon-2017-0160.","journal-title":"Future Oncol"},{"key":"1390_CR71","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1614359.","journal-title":"N Engl J Med"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01390-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01390-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01390-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:41:43Z","timestamp":1669902103000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01390-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1390"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01390-5","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the ethics committee of the Physician\u00b4s Chamber of Westphalia-Lippe and the medical faculty of the University of Muenster (2007\u2013524-f-S and 2007\u2013390-f-S) before the study began. All animal experiments in this study were carried out in accordance with the recommendations of the Institutional Animal Care and Use Committee \u201cLandesamt f\u00fcr Natur, Umwelt und Verbraucherschutz NRW\u201d (LANUV). This study was performed with permission of the Institutional Animal Care and Use Committee and of the local veterinary administration of Muenster (Permit Numbers 84\u201302.04.2014.A193 and 81\u201302.04.2019.A341).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NB, LW, AF, GL, WEB, SB have filed patent applications on electrostatic nanocarrier technology. All other authors disclose no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}